Mostrar el registro sencillo del ítem
Aspectos éticos del tratamiento del acné con isotretinoina oral en mujeres en edad fértil
dc.contributor.advisor | Arango Restrepo, Pablo | |
dc.contributor.author | Tovar Cock, Álvaro José | |
dc.date.accessioned | 2019-02-12T14:50:51Z | |
dc.date.available | 2019-02-12T14:50:51Z | |
dc.date.issued | 2018-05-08 | |
dc.identifier.uri | http://hdl.handle.net/10818/34942 | |
dc.description | 34 páginas | es_CO |
dc.description.abstract | Desde la época de Sócrates, Aristóteles y Platón se habló de Ética, sin embargo el concepto de Bioética nace alrededor del año 1970 ante los abusos de la ciencia en la investigación con seres humanos y en otros seres vivos. Ésta no es más que la aplicación de la Ética en las ciencias de la vida, planteada por Van Rensselaer Potter, razón por la que en Medicina existe un compromiso a tener en cuenta dichos planteamientos, debido a que se trabaja con seres humanos. | es_CO |
dc.format | application/pdf | es_CO |
dc.language.iso | spa | es_CO |
dc.publisher | Universidad de La Sabana | es_CO |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.source | Universidad de La Sabana | |
dc.source | Intellectum Repositorio Universidad de La Sabana | |
dc.subject | Bioética | es_CO |
dc.subject | Acné | es_CO |
dc.subject | Isotretinoína | es_CO |
dc.subject | Mujeres | es_CO |
dc.title | Aspectos éticos del tratamiento del acné con isotretinoina oral en mujeres en edad fértil | es_CO |
dc.type | bachelor thesis | es_CO |
dc.identifier.local | 268243 | |
dc.identifier.local | TE09543 | |
dc.type.hasVersion | publishedVersion | es_CO |
dc.rights.accessRights | openAccess | es_CO |
dcterms.references | Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). (junio de 2015). Guía del farmacéutico para la dispensación de Isotretinoína. Obtenido de Programa de prevención de embrazos de Isotretinoína: https://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=verAnexo&CDoliId=289 | |
dcterms.references | American Academy of Dermatology. (1 de may de 2014). Code of medical ethics for dermatologists. Obtenido de Administrative regulations: https://www.aad.org/Forms/Policies/Uploads/AR/AR%20CODE%20OF%20MEDICAL %20ETHICS%20FOR%20DERMATOLOGISTS.pdf | |
dcterms.references | Bloom, K., & Bercovitch, L. (2012). Autonomy, Isotretinoin and iPLEDGE: The ethics of burdensome regulation and use of teratogenic medication. En L. Bercovitch, & C. Perlis, Dermatoethics: Contemporary Ethics and professionalism in Dermatology (págs. 19-24). Philadelphia: Springer. | |
dcterms.references | Centers for Disease Control and Prevention. (2000). Accutane-exposed pregnancies-California. MMWR Morb Mortal Wkly Rep, 49(2), 28-31. Obtenido de https://www.ncbi.nlm.nih.gov/pubmed/10680601 | |
dcterms.references | Centro Dermatológico Federico Lleras Acosta, ESE. (2016). Perfil Epidemiológico. Bogotá, D. C.: Centro Dermatológico Federico Lleras Acosta | |
dcterms.references | Cox, N., & Coulson, I. (2010). Diagnosis of skin disease, in rook's textbook of dermatology (8th ed.). Oxford, UK.: Burns, T.; Breathnach, S.; Cox, N.; Griffiths, C.; Wiley-Blackwell | |
dcterms.references | Cunliffe, W. J., & Gollnick, H. P. (2001). Acne. En W. J. Cunliffe, & H. P. Gollnick, Diagnosis and Management (págs. 49-67). London, UK: Martin Dunitz Ltd | |
dcterms.references | Dai, W., Labraico, J., & Stern, R. (1992). Epidemiology of isotretinoin exposure during preganancy. Journal of the American Academy of Dermatology, 24(4), 599-606 | |
dcterms.references | Doshi, A. (2007). The cost of clear skin: balancing the social and safety cost of IPLEDGE with the efficacy of Accutane (Isotretinoin). Seton Hall Law Rev, 1(37), 625-660. | |
dcterms.references | Goulden, V., Stables, G., & Cunliffe, W. (1999). Prevalence of facial acne in adults. J Am Acad Dermatol, 41(4), 577-580. | |
dcterms.references | Hassun, K. (2000). Etiopatogenia da acne. An Bras Dermatol, 1(75), 7-15. | |
dcterms.references | Huber, M. (February de 2004). Review of data from SMART program. Obtenido de FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting: http://www.fda.gov/ohrms/dockets/ac/04/slides/4017s1.htm | |
dcterms.references | Juan Pablo II. (25 de marzo de 1995). Carta encíclica Evangelium vitae. Obtenido de Vaticano - Documentos: http://w2.vatican.va/content/john-paul-ii/es/encyclicals/documents/hf_jpii_enc_25031995_evangelium-vitae.html | |
dcterms.references | Kaminsky, A., Ferahbas, A., Turan, M., & Esel, E. (2004). A pilot study evaluating anxiety and depressive scores in acne patients treated with isotretinoin. J Dermatolog Treat, 1(15), 153-157 | |
dcterms.references | Lammer, E., Chen, D., Hoar, R., Agnish, N., Benke, ,. P., Braun, J., & Sun, S. (1985). Retinoic Acid Embryopathy. The New England Journal of Medicine, 313(14), 837-841. doi:10.1056/NEJM198510033131401 | |
dcterms.references | Layton, A., Seukeran, D., & Cunliffe, W. (1997). Scarred for life? Dermatology, 195(Suppl 1), 38-40. | |
dcterms.references | Maloney, M., & Stone, S. (2011). Isotretinoin and IPLEDGE: a view and results. J Am Acad Dermatol, 65(2), 418-421. doi:10.1016/j.jaad.2011.04.006 | |
dcterms.references | Peck, G., Olsen, T., & Butkus, D. (1982). Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol, 1(6), 735-745. | |
dcterms.references | Peck, G., Yoder, F., & Olsen, T. (1978). Treatment of Darier’s disease, lamellar ichthyosis, pityriasis rubra pilaris, cystic acne and basal cell carcinoma with oral 13-cis-retinoic acid. Dermatological, 137(suppl 1), 11-12. | |
dcterms.references | Pochi, P. (1990). The pathogenesis and treatment of acne. Annu Rev Med, 1(41), 187-98. | |
dcterms.references | Prevost, N. (2013). Isotretinoin: Update on Controversial Issues. J Pediatr Adolesc Gynecol, 26:290-3. | |
dcterms.references | Rook, A. (2010). Text Book of Dermatology. Londres: Lippincot. | |
dcterms.references | Sánchez, Q. (2003). Metabolitos de la isotretinoína principales responsables de sus efectos terapéuticos y adversos. Rev Chil Dermatol, 1(19), 14-23. | |
dcterms.references | Sardana, K., & Sehgal, V. (2003). Retinoids: fascinating up-andcoming scenario. J Dermatol, 1(30), 355-380. | |
dcterms.references | Saurat, J. (1992). Side effects of systemic retinoids and their clinical management. J Am Acad Dermatol, 1(27), 523-528. | |
dcterms.references | Seek, J., Koren, G., & Nulman, I. (2013). Pregnancy and isotretinoin therapy. CMAJ - JAMC, 185(5), 411-413. doi:10.1503/cmaj.120729 | |
dcterms.references | Sgreccia, E. (2014). Manual de Bioética. Madrid, España: BAC. | |
dcterms.references | Shalita, et al. (2003). Current concepts in the treatment of acne: Report from a clinical roundtable. Cutis, 72(Suppl 1), 1-13. | |
dcterms.references | Sladden, M., & Harman, E. (2007). What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin? Archives Dermatology, 143(9), 1187-1188. Obtenido de https://pdfs.semanticscholar.org/b924/247a0a306a2f979308d43535e5c9def17409.pdf | |
dcterms.references | Stern, R. (1989). When a Uniquely Effective Drug is Teratogenic. The case of isotretinoin. N Engl J Med, 320(15), 1007-1009. Obtenido de https://www.ncbi.nlm.nih.gov/pubmed/2522591 | |
dcterms.references | Sulzberger, M., & Zaidems, S. (1948). Psychogenic factors in dermatological disorders. Med Clin North Am, 1(32), 669-673. | |
dcterms.references | Teichert, M., Visser, L., Dufour, M., Rondenburg, E., Straus, S., Smet., D., & Stricker, B. (2010). Isotretinoin use and compliance with the dutch pregnancy prevention programme. A retrosprective cohort study in females of reproductive age using pharmacy dispensing data. Drug Safety, 33(4), 315-326. | |
dcterms.references | US Food and Drug Administration. (2015). IPLEDGE . Obtenido de Committed by pregnancy prevention: https://www.ipledgeprogram.com/default.aspx | |
dcterms.references | Vélez, H., Rojas, W., Borrero, J., & Restrepo, J. (2006). Terapia Dermatológica. Fundamentos de Medicina. Medellín, Colombia: Corporación para investigaciones biológicas. | |
dcterms.references | White, G. M. (1998). Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol, 39(2), S34-47 | |
dcterms.references | Wolff, K., Goldsmith, L., & Katz, S. (2009). Dermatología en medicina general (7ª ed.). Bogotá, D. C.: Editorial Panamericana. | |
dcterms.references | Zeichner, J. (2013). Isotretinoin updates. Dermatol Ther, 1(26), 377-389. | |
dcterms.references | Zhanel, et al. (2004). The glycylcyclines: a comparative review with the tetracyclines. Drugs(64), 63-88. | |
dcterms.references | Zouboulis, C., & Piquero-Martin, J. (2003). Update and future of systemic acne treatment. Dermatologica(206), 37-53. | |
thesis.degree.discipline | Facultad de Medicina | es_CO |
thesis.degree.level | Especialización en Bioética | es_CO |
thesis.degree.name | Especialista en Bioética | es_CO |